ArcBest Corporation logo ARCB - ArcBest Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
1
BUY 11
HOLD 11
SELL 1
STRONG
SELL
0
| PRICE TARGET: $117.14 DETAILS
HIGH: $150.00
LOW: $85.00
MEDIAN: $117.00
CONSENSUS: $117.14
DOWNSIDE: 5.96%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Cyclical & Capital-Intensive 80% confidence

Primary model: Normalized Earnings × Cycle Multiple

Valuation Signal Overvalued Strong
Trading 182.2% above fair value
Current Price $124.57
Bear Case $17.66 85.8% downside ($17.66 - $124.57) / $124.57 = -85.8% $7.93 × 4x + net cash
Fair Value $44.15 64.6% downside ($44.15 - $124.57) / $124.57 = -64.6% $7.93 × 6x + net cash
Bull Case $70.66 43.3% downside ($70.66 - $124.57) / $124.57 = -43.3% $7.93 × 7x + net cash

Adjust Assumptions

5.5x
7.93$

Key Value Driver

Through-cycle normalized EPS ($7.93)

Implied Market Multiple 15.7x

Plain-Language Summary

Our base-case estimate uses Normalized Earnings × Cycle Multiple. We then blend that result with the average analyst price target of $117.14 from 24 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $44.15 per share.

Warnings

This company has a built-in lending arm whose debt is mixed in with the main business. We capped the debt adjustment to avoid overstating what the core business owes.
Price-to-book value of 3.0x is above the normal range for this type of business (0.7x-2.0x). The stock may already price in a strong cycle.
Wall Street's average price target is $117.14 (from 24 analysts). Our estimate is 83% below the consensus -- consider that gap carefully.

Key Risks

  • Standard 10-year DCF produces unreliable terminal values for cyclicals
  • 'Cheap' P/E at cycle peak is the most common value trap — normalize first
  • Captive finance subsidiaries have different risk profiles from manufacturing